Ar101 | search
Click here to view Ar101 news from 60+ newspapers.
Bookmark or Share- FDA approves first drug for treatment of peanut allergy for childrenToday the U.S. Food and Drug Administration approved Palforzia [Peanut (Arachis hypogaea) Allergen Powder-dnfp] to mitigate allergic reactions, including anaphylaxis, that may occur with...
- AR101 Oral Immunotherapy for Peanut Allergy | NEJMAR101 is a new peanut-derived, oral biologic drug that delivers a target daily maintenance dose of 300 mg of peanut protein with a characterized protein profile.
- FDA Approves AR101 as First Peanut Allergy Immunotherapy - HCP LiveAR101 (Palforzia), an oral peanut-protein immunotherapy from Aimmune Therapeutics, has been approved for the reduction of allergic reaction incidence and severity in patients aged 4-17 years old with a peanut allergy.
- Efficacy and Safety of AR101 in Oral Immunotherapy for Peanut ... - PubMedIn this study, AR101 demonstrated an acceptable safety profile and demonstrated clinical activity as a potential immunomodulatory treatment option in peanut-allergic children over the age of 4, adolescents, and young adults.
- AR101, Vascular EDS Therapy, Cleared by FDA to Enter Pivotal TrialAR101 (enzastaurin), an orally available small molecule being developed to treat vascular Ehlers-Danlos syndrome (vEDS) by Aytu BioPharma, has been designated an orphan drug by the U.S. Food and Drug Administration (FDA).
More
